psychedelics investing Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
psychedelics investing Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
psychedelics investing Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
psychedelics investing Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
psychedelics investing Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression
Silver47 and Summa Silver Announce Closing of $6.9 Million Brokered Financing, Including Full Exercise of the Over-Allotment Option
Hempalta Issues Open Call for Strategic Partnerships to Scale Alberta-Based Nature-Based Carbon Program
